Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:person
|
| gptkbp:birthPlace |
gptkb:London,_Ontario,_Canada
|
| gptkbp:dateOfBirth |
1959
|
| gptkbp:degree |
BSc
MBA |
| gptkbp:education |
gptkb:Duke_University
gptkb:University_of_Virginia |
| gptkbp:employer |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:fieldOfWork |
pharmaceutical industry
|
| https://www.w3.org/2000/01/rdf-schema#label |
J. Michael Pearson
|
| gptkbp:nationality |
gptkb:American
gptkb:Canadian |
| gptkbp:notable_for |
aggressive acquisition strategy at Valeant
controversy over drug pricing |
| gptkbp:occupation |
gptkb:business_executive
|
| gptkbp:position_held |
CEO of Valeant Pharmaceuticals
|
| gptkbp:predecessor |
gptkb:Timothy_G._Tyson
|
| gptkbp:successor |
gptkb:Joseph_Papa
|
| gptkbp:termEnd |
2016
|
| gptkbp:termStart |
2008
|
| gptkbp:bfsParent |
gptkb:Wesco_Financial
|
| gptkbp:bfsLayer |
5
|